List of Excipients in Branded Drug AVEED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	AVEED	testosterone undecanoate	67979-511	BENZYL BENZOATE	2027-03-14
Endo USA Inc	AVEED	testosterone undecanoate	67979-511	CASTOR OIL	2027-03-14

AVEED Excipient Strategy and Commercial Opportunities in Testosterone Undecanoate Injection

Last updated: August 18, 2026

AVEED is a long-acting intramuscular testosterone undecanoate injection containing 750 mg in 3 mL. Its excipient system is commercially important because the formulation must solubilize a highly lipophilic steroid, remain injectable through a large-bore needle, support depot release, and limit injection-related safety risks. The principal opportunity is not a simple excipient substitution. It is a differentiated long-acting injectable platform that reduces viscosity, improves tolerability, simplifies administration, or supports a lower-risk regulatory pathway.

What excipients are used in AVEED?

AVEED contains testosterone undecanoate dissolved in a vehicle composed of benzyl benzoate and refined castor oil. The formulation is supplied as a 750 mg/3 mL intramuscular injection and is administered in the gluteal muscle by a healthcare professional.[1]

Attribute	AVEED profile
Active ingredient	Testosterone undecanoate
Strength	750 mg per 3 mL
Route	Intramuscular
Dosage form	Long-acting oil-based injection
Principal excipients	Benzyl benzoate and refined castor oil
Administration	Deep gluteal injection
Initial dosing	Second injection at 4 weeks
Maintenance dosing	Every 10 weeks
Administration risk	Pulmonary oil microembolism and anaphylaxis
Observation requirement	30 minutes after injection
FDA approval	March 2014
Regulatory pathway	New drug application

The formulation is preservative-free in the conventional multidose-vial sense. Benzyl benzoate acts primarily as a co-solvent and vehicle component rather than as a conventional antimicrobial preservative. Castor oil provides the continuous lipid phase and contributes to the depot effect.

Why does AVEED require benzyl benzoate and castor oil?

Testosterone undecanoate has very low aqueous solubility. A lipid-based vehicle is therefore required to deliver a high dose in a small injection volume. The vehicle must maintain drug solubility during storage while permitting precipitation or slow release after intramuscular administration.

Benzyl benzoate has several formulation functions:

• It improves solubilization of testosterone undecanoate.
• It reduces the amount of oil required to maintain drug in solution.
• It modifies viscosity and drug-release behavior.
• It can improve manufacturability compared with a formulation based solely on high-viscosity oil.

Castor oil provides the depot matrix. Its high viscosity can slow drug diffusion and support sustained exposure, but it also creates commercial and clinical constraints. A viscous formulation can increase injection force, prolong administration time, complicate prefilled-syringe development, and affect patient comfort.

The excipient system must be evaluated as a combined vehicle. Substituting benzyl benzoate or changing the oil phase can alter solubility, precipitation kinetics, particle formation, local tolerability, pharmacokinetics, and systemic safety.

What excipient attributes determine commercial viability?

The main technical variables are listed below.

Excipient attribute	Commercial relevance
Testosterone undecanoate solubility	Determines dose concentration and injection volume
Viscosity	Affects needle gauge, injection force, administration time and device compatibility
Physical stability	Controls precipitation, crystallization and shelf life
Local tolerability	Influences pain, nodules, inflammation and prescriber adoption
Oxidative stability	Affects impurities and long-term storage
Extractables and leachables	Limits compatibility with elastomers, syringes and autoinjectors
Regulatory history	Affects 505(b)(2), ANDA or NDA development risk
Supply security	Determines exposure to single-source or specialized excipient manufacturing
Sterilization compatibility	Affects terminal sterilization and aseptic-processing options
Injection safety	Can influence pulmonary oil microembolism and hypersensitivity risk

For a follow-on product, the most defensible target product profile would preserve testosterone undecanoate exposure while improving one or more of the following: injection volume, viscosity, pain, storage stability, administration time, device compatibility, or observation burden.

What formulation patents and intellectual-property issues affect AVEED?

AVEED’s intellectual-property position can include several layers:

1. Composition patents. These may cover testosterone undecanoate dissolved in defined oil and co-solvent systems.
2. Concentration and dosage-form patents. Claims may cover high-concentration intramuscular formulations, vial configurations, or specific dose volumes.
3. Pharmacokinetic patents. Claims may address dosing intervals, testosterone exposure profiles, or maintenance regimens.
4. Method-of-use patents. These may cover treatment of testosterone deficiency, hypogonadism, or dosing schedules.
5. Manufacturing patents. Claims can cover dissolution, filtration, filling, sterilization, or control of crystal formation.
6. Device and administration patents. Syringes, needle configurations, packaging and administration procedures may create additional barriers.

The Orange Book should be checked for the current patent listings, expiration dates, pediatric exclusivity, and any changes in listed patents.[2] Patent expiry alone does not eliminate regulatory risk. A follow-on developer must also address formulation similarity, pharmacokinetic comparability, injection-site effects, manufacturing controls, and the product’s pulmonary oil microembolism risk.

Are Paragraph IV challenges relevant to AVEED?

A Paragraph IV challenge could target listed patents claiming the composition, method of use, or dosing regimen. The commercial value of such a challenge depends on whether the challenger can demonstrate non-infringement or invalidity while maintaining a sufficiently similar product for FDA approval.

An ANDA strategy is difficult if the proposed product uses a materially different excipient system or changes the release profile. A 505(b)(2) application is more flexible for a reformulated or improved product, but it requires reliance on FDA findings for the reference product and may require new clinical or pharmacokinetic data.

A formulation that uses different excipients, a different oil phase, or a different concentration can create both freedom-to-operate opportunities and additional regulatory work.

What regulatory pathway is most suitable for an AVEED follow-on?

ANDA pathway

An ANDA is most attractive when the proposed product can match AVEED in active ingredient, strength, dosage form, route, and key performance characteristics. The applicant would need to establish pharmaceutical equivalence and bioequivalence under FDA requirements.

The limitations are significant:

• A different vehicle may undermine pharmaceutical equivalence.
• Long-acting intramuscular products can have complex pharmacokinetics.
• Injection-site tolerability may require comparative evaluation.
• The applicant must address the reference product’s labeling and safety profile.
• Device or administration differences can complicate equivalence.

505(b)(2) pathway

A 505(b)(2) application is the more practical route for a differentiated excipient system. It could support:

• A lower-viscosity oil vehicle.
• A different co-solvent system.
• A reduced injection volume.
• An alternative depot-release profile.
• A new presentation such as a prefilled syringe.
• A modified administration schedule, if supported by clinical evidence.

The 505(b)(2) route does not eliminate patent litigation. It can require certification against listed patents and may trigger a 30-month stay after a timely Paragraph IV notice.[3]

Full NDA pathway

A full NDA would be appropriate for a substantially different delivery system, such as a non-oil depot, implant, or novel long-acting platform. The development cost and clinical burden would be much higher, but the product could obtain stronger differentiation and a broader intellectual-property position.

What excipient alternatives could improve AVEED?

Alternative vegetable oils

Potential alternatives include sesame oil, cottonseed oil, medium-chain triglycerides, and other pharmaceutically qualified lipid vehicles. Each alternative presents different risks.

Candidate vehicle	Potential advantage	Main development risk
Sesame oil	Established injectable precedent	Allergenicity, oxidation and supply variability
Cottonseed oil	Injectable precedent and lower viscosity potential	Regulatory history and impurity control
Medium-chain triglycerides	Lower viscosity and oxidation resistance	Depot behavior may differ materially
Ethyl oleate	Solvent capacity and lower viscosity	Local tolerability and formulation stability
Squalene or related lipids	Potential solubilization and depot properties	Limited injectable precedent and regulatory burden
Synthetic triglycerides	Batch consistency and controlled composition	Higher cost and new excipient qualification

The strongest near-term opportunity is a lower-viscosity lipid vehicle with a well-established parenteral history. A novel excipient can improve performance but will increase FDA review complexity and may require a broader toxicology package.

Alternative co-solvents

Benzyl alcohol, ethanol, propylene glycol, polyethylene glycol derivatives, and ethyl oleate may be considered in screening programs. Their usefulness is limited by injection-site tolerance, systemic exposure, precipitation risk, and compatibility with long-term depot release.

A substitute co-solvent must maintain testosterone undecanoate in solution during storage without creating excessive supersaturation after injection. Rapid precipitation can produce local crystalline drug deposits, inconsistent absorption, or injection-site reactions.

Surfactants and precipitation-control agents

Surfactants can improve wetting and reduce interfacial instability, but parenteral use is constrained by local irritation, hemolysis, immunogenicity concerns, and oxidative degradation. They are more likely to support a specialized formulation than a straightforward generic substitution.

What commercial opportunities exist in AVEED excipients?

Lower-viscosity injectable formulation

This is the most direct opportunity. A formulation that reduces injection force could allow:

• Smaller needles.
• Shorter administration times.
• Better compatibility with prefilled syringes.
• Lower risk of incomplete dose delivery.
• Improved clinic workflow.

The product would still require evidence that exposure and depot duration remain comparable.

Reduced injection volume

AVEED requires a 3 mL injection. A higher-concentration formulation could create value by reducing volume, but testosterone undecanoate solubility and local tolerability place practical limits on concentration increases.

A 1.5 to 2 mL presentation could be commercially meaningful if it preserves the 10-week maintenance interval and does not increase local adverse events.

Prefilled syringe or administration-ready presentation

A prefilled syringe could reduce preparation steps, dosing errors, and contamination risk. The formulation would need to pass container-closure, syringe compatibility, silicone-oil, stopper, needle, and extractables-and-leachables studies.

A prefilled syringe would not automatically remove the need for post-injection observation because that requirement is tied to the product’s safety risks, not only to vial handling.

Excipient supply and dual sourcing

AVEED depends on pharmaceutical-grade benzyl benzoate and refined castor oil with controlled impurity profiles. Suppliers can create value through:

• Dual-source qualification.
• Low-peroxide oil grades.
• Consistent fatty-acid profiles.
• Injectable-grade benzyl benzoate.
• Global regulatory-support packages.
• Dedicated capacity and change-control commitments.

For a marketed long-acting injectable, supply reliability can be as important as marginal cost. Excipient changes can trigger comparability assessments, stability work, and regulatory submissions.

Improved storage stability

An excipient system with lower oxidation, reduced precipitation, and improved container compatibility could extend shelf life or support broader temperature excursions. Stability improvements are commercially valuable in hospital, specialty-pharmacy, and international distribution channels.

How does AVEED compare with competing testosterone products?

Product category	Typical administration	Excipient strategy	Commercial implication
AVEED	Long-acting intramuscular injection	Castor oil plus benzyl benzoate	Long dosing interval, but clinic administration and observation burden
Testosterone cypionate	Shorter-interval injection	Oil-based depot formulation	Lower product complexity but more frequent dosing
Testosterone enanthate	Shorter-interval injection	Oil-based depot formulation	Competes on familiarity and availability
Transdermal gel or patch	Daily topical use	Semi-solid or polymeric vehicle	Avoids injection but has adherence and transfer concerns
Oral testosterone undecanoate	Oral dosing	Lipid-based absorption system	Avoids injection, but requires oral dosing and different safety monitoring
Testosterone pellets	Implantation every several months	Solid depot	Long duration, but requires a procedure

AVEED’s commercial position depends on whether patients and prescribers value a 10-week dosing interval enough to accept deep gluteal administration and 30 minutes of observation. An improved excipient system could strengthen that position without changing the active ingredient.

What FDA safety requirements affect formulation commercialization?

FDA labeling identifies pulmonary oil microembolism and anaphylaxis as important risks. Patients must be observed for 30 minutes after each injection.[1] The risk profile is central to formulation development.

A new excipient system should be assessed for:

• Droplet or oil-phase behavior during injection.
• Accidental intravascular administration risk.
• Particle generation after injection.
• Local tissue irritation.
• Hypersensitivity potential.
• Injection-site nodules or pain.
• Changes in absorption rate.
• Effects of needle gauge and injection speed.

A formulation that reduces viscosity but increases dispersibility could have conflicting effects on safety. The development program must evaluate the entire administration system, including formulation, syringe, needle, injection technique, and training.

Which companies could participate in the AVEED excipient opportunity?

The opportunity spans several supplier categories:

• Specialty excipient manufacturers with injectable-grade oils.
• Lipid-formulation companies with depot-delivery platforms.
• Pre-filled syringe and device manufacturers.
• Contract development and manufacturing organizations.
• Generic and 505(b)(2) developers.
• Testosterone-product marketers seeking longer-acting formulations.
• Pharmaceutical packaging companies with low-interaction container systems.

The strongest commercial candidates are companies that can provide both excipient supply and formulation-development support. A commodity supplier with no injectable regulatory package is less attractive because the formulation’s clinical and regulatory risk is concentrated in the vehicle.

What is the revenue exposure and market opportunity?

AVEED revenue is generally reported within the sponsor’s broader pharmaceutical portfolio rather than as a separately detailed public segment. The product’s value derives from its recurring maintenance schedule, specialist prescribing, and differentiated duration rather than from a high-volume primary-care market.

Commercial upside could come from:

1. Increasing persistence through fewer annual administrations.
2. Reducing clinic preparation and administration time.
3. Expanding use through improved tolerability.
4. Supporting broader specialty-pharmacy distribution.
5. Licensing a lower-viscosity or smaller-volume formulation.
6. Developing a generic or 505(b)(2) alternative after key exclusivity barriers expire.

A reformulated product could compete on total treatment economics even if its acquisition price is higher. Relevant measures include visits per year, administration labor, observation-chair utilization, missed-dose frequency, and patient discontinuation.

How strong is the AVEED formulation opportunity?

The opportunity is technically credible but development-intensive.

Criterion	Assessment
Excipient substitution potential	Moderate
Need for formulation screening	High
Bioequivalence complexity	High
Device integration opportunity	High
Regulatory pathway flexibility	Moderate to high through 505(b)(2)
Risk of patent overlap	Moderate to high
Supply-chain opportunity	Moderate
Commercial differentiation	High if injection burden improves
Probability of simple generic substitution	Limited

The most attractive strategy is a staged program: screen qualified low-viscosity vehicles, characterize testosterone undecanoate solubility and precipitation, select a formulation compatible with a prefilled syringe, and pursue a 505(b)(2) strategy if the product materially differs from AVEED.

Key Takeaways

• AVEED uses testosterone undecanoate in a benzyl benzoate and refined castor oil vehicle.
• The excipient system controls solubility, viscosity, depot release, injection force, and local tolerability.
• Lower-viscosity formulations and smaller injection volumes offer the clearest commercial opportunities.
• A prefilled syringe could improve clinic workflow but would not eliminate the 30-minute observation requirement.
• A materially different vehicle is more likely to require a 505(b)(2) application than a straightforward ANDA.
• Patent review should cover composition, dosing regimen, method of use, manufacturing, packaging, and device claims.
• The main commercial risk is that improving viscosity or solubility may change pharmacokinetics, precipitation behavior, or pulmonary oil microembolism risk.
• Excipient suppliers with injectable regulatory support and dual-source capacity have a stronger position than commodity suppliers.

FAQs

Can AVEED be reformulated with sesame oil?

Potentially, but the change would require comparative evaluation of solubility, viscosity, depot release, local tolerance, stability, and pharmacokinetics. Sesame oil has injectable precedent but would not be a low-risk substitution.

Could a generic AVEED use different excipients?

A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, safety, and bioequivalence. A materially different vehicle may shift the product toward a 505(b)(2) pathway.

Would a smaller AVEED injection improve patient adoption?

A smaller injection could reduce discomfort and administration burden, but adoption would depend on whether higher drug concentration increases local reactions or changes the dosing interval.

Can a lower-viscosity formulation remove the AVEED REMS or observation requirement?

Not automatically. The safety program is linked to pulmonary oil microembolism and anaphylaxis risk. FDA would need evidence that the reformulated product has a materially different risk profile.

What is the most valuable excipient-development target for testosterone undecanoate?

The leading target is a lower-viscosity, oxidation-controlled lipid vehicle that maintains long-acting pharmacokinetics and is compatible with a prefilled syringe.

References

1. U.S. Food and Drug Administration. (2023). AVEED (testosterone undecanoate) injection prescribing information. Endo Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2

4. U.S. Food and Drug Administration. (2013). ANDAs for certain highly purified synthetic peptides that reference peptide drug products. FDA Guidance for Industry.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.